Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Uno studio interventistico per confrontare l'efficacia e la sicurezza della tafenochina (TQ) e della primachina (PQ) quando entrambe vengono assunte insieme alla clorochina (CQ) per il trattamento della malaria da P. Vivax in partecipanti indiani di età pari o superiore a 2 anni

28 settembre 2026 aggiornato da: GlaxoSmithKline

Uno studio interventistico di fase 3 randomizzato, in aperto, multicentrico sull'efficacia e. Sicurezza della tafenochina rispetto alla primachina (entrambi somministrati in concomitanza con la clorochina) per la cura radicale (prevenzione delle recidive) della malaria da Plasmodium Vivax (P. Vivax) nei partecipanti indiani (popolazione pediatrica e adulta)

The aim of this study is to collect efficacy and safety data to support the registration of tafenoquine in India.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Stimato)

324

Fase

  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

      • Ahmedabad, India, 380008
        • Reclutamento
        • GSK Investigational Site
        • Contatto:
        • Contatto:
        • Investigatore principale:
          • Leena Dabhi
      • Bikaner, India, 334001
        • Reclutamento
        • GSK Investigational Site
        • Contatto:
        • Contatto:
        • Investigatore principale:
          • Sanjay Kumar Kochar
      • Kolkata, India, 700073
        • Reclutamento
        • GSK Investigational Site
        • Contatto:
        • Contatto:
        • Investigatore principale:
          • Arunansu Talukdar
      • Mumbai, India, 400012
        • Reclutamento
        • GSK Investigational Site
        • Contatto:
        • Contatto:
        • Investigatore principale:
          • Nithya Gogtay
      • Surat, India, 395004
        • Reclutamento
        • GSK Investigational Site
        • Contatto:
        • Contatto:
        • Investigatore principale:
          • Shailesh Jethwa

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 2 anni a 64 anni (Bambino, Adulto)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Males and females >=2 years of age and under (<) 65 years of age, weighing >10 kg.

  2. The participant has a positive malarial smear for P. vivax with a parasite density of >100/microliter and <100,000/microliter.

  3. The participant has a screening Hb value >8 g/dL.

  4. The participant has an axillary temperature of 37.5°C or history of fever 48 hours before recruitment.

  5. The participant has a G6PD value (measured using the SD Biosensor STANDARDTM G6PD test) 6.1 units/gram (U/g) Hb for G6PD activity (6.1 U/g Hb cut-off is applicable for both males and females).

  6. A female participant is eligible to participate if she is not pregnant or breastfeeding, and if one of the following conditions applies:

    • Is a woman of non-childbearing potential (WONCBP) as defined in
    • Is a Women of Childbearing Potential (WOCBP) and using a contraceptive method that is highly effective (with a failure rate of <1% per year), with low user dependency, during the study intervention period and for at least 90 days after the last dose of study intervention. The investigator should evaluate the potential for contraceptive method failure (e.g., noncompliance, recently initiated) in relationship to the first dose of study intervention. The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.
  7. A WOCBP must test negative on a highly sensitive pregnancy test (urine or serum as required by local regulations) before the first dose of study intervention.

  8. The participant is willing and able to comply with the procedures described in the study protocol. The participant or parent/legal guardian, as applicable, has given written informed, dated consent; and the participant has given written assent, if applicable, to participate in the study.

Exclusion Criteria:

  1. The participant has severe P. vivax malaria as defined by WHO criteria [WHO, 2023].

  2. The participant has a mixed malaria infection (identified by a malarial smear).

  3. The participant has a condition that may affect absorption of study medication, such as severe vomiting (no food or inability to take food during the previous 8 hours).

  4. The participant has a history of porphyria, psoriasis, or epilepsy.

  5. The participant has a history of allergy, intolerance to or a known contraindication to the use of mefloquine (or other aryl amino alcohol drugs), chloroquine, tafenoquine, primaquine, any other 4- or 8-AQ or any of their respective excipients.

  6. The participant has received treatment with any investigational drug within 30 days of study entry, or within 5 half-lives, whichever is longer.

  7. The participant has previously enrolled in this study.

  8. The participant has a recent history of illicit drug abuse or heavy alcohol intake that in the opinion of the investigator could compromise full participation in the study or adherence to study procedures.

  9. Participants with a current or past history of serious psychiatric disorders.

  10. The participant has a clinically significant concurrent illness (e.g., pneumonia, tuberculosis, meningitis, septicemia, dengue, coagulopathy, severe hemorrhage, or febrile convulsions prior to consent) or a pre-existing condition (e.g., renal disease, malignancy, or severe malnutrition according to WHO child growth standards) or systemic disease predisposing patients to suffer from granulocytopenia, such as rheumatoid arthritis and lupus erythematosus or severe ocular disease.

  11. The participant is known to be HIV-infected and/or is currently on antiretroviral therapy.

  12. The participant is regularly using drugs with hemolytic potential.

  13. The participant has a QT corrected by Fridericia's formula (QTcF) >450 msec, evidence of bradycardia (<50 beats per min) or ventricular arrhythmias on the screening ECG, a history of cardiac disease (e.g., myocardial infarction, congenital heart disease, or arrhythmia), hypokalemia (<2.9 millimoles per liter [mmol/L]) or hyperkalemia (>=6.0 mmol/L) at Screening.

  14. The participant has taken drugs with antimalarial activity (e.g., artemisinin-based combination therapies, mefloquine, primaquine, chloroquine, tafenoquine or any other 4-AQ) within 30 days prior to study entry.

  15. The participant has taken or will likely require during the study the use of:

    1. Histamine-2 blockers (restricted to first 3 days whilst receiving CQ)
    2. Antacids (restricted to first 3 days whilst receiving CQ)
    3. Drugs of the biguanide class (i.e., phenformin, metformin, buformin)
    4. Anti-arrhythmic agents (i.e., dofetilide, procainamide, pilsicainide)
    5. Medications that prolong the QTc interval
  16. The participant has liver transaminases (ALT/AST) >2 times the upper limit of normal (ULN).

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: TQ/CQ

Participants in this group receive a single dose of TQ on Day 1 or Day 2 and a single dose of CQ daily, on Days 1 to 3.

A single dose of TQ will be administered orally on Day 1 or Day 2.

A single dose of CQ will be administered orally, daily, on Days 1 to 3.

Comparatore attivo: PQ/CQ

Participants in this group receive a single dose of PQ daily from Day 1 or 2, up to Day 14 (or Day 15 if PQ started on Day 2) and a single dose of CQ daily, on Days 1 to 3.

A single dose of CQ will be administered orally, daily, on Days 1 to 3.

A single dose of PQ will be administered orally, daily, on Day 1 or 2 to Day 14 (or Day 15 if PQ started on Day 2).

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Number of participants remaining recurrence-free during the 6 months post-treatment and have a negative blood smear at the Month 6 (end of study [EOS]) visit
Lasso di tempo: Up to Month 6

Two consecutive negative blood smears between Day 2 and Day 8, no positive blood smear for P. vivax parasites at any point during the 6-month follow-up period, and a negative P. vivax smear at the 6-month assessment.

Up to Month 6

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Numero di morti
Lasso di tempo: Fino al mese 6
Fino al mese 6
Parametri di laboratorio che soddisfano i criteri >= Divisione dell'AIDS (DAID) Grado 3
Lasso di tempo: Fino al mese 6
Fino al mese 6
Parametri dei segni vitali che soddisfano i criteri >=DAID di Grado 3
Lasso di tempo: Fino al mese 6
Fino al mese 6
Variazione rispetto al basale ad ogni visita dello studio per i parametri ematologici (percentuale di reticolociti)
Lasso di tempo: Ai giorni 5, 8, 15, 29, 60, 90, 120, 150 e 180
Ai giorni 5, 8, 15, 29, 60, 90, 120, 150 e 180
Number of participants with clinically relevant hemolysis change from baseline
Lasso di tempo: Up to Day 14

A decrease in hemoglobin of greater than or equal to (>=) 30% or greater than (>) 3g/deciliter (dL) from baseline; or an overall drop in hemoglobin below 6.0 g/dL or complications thereof (e.g., required transfusions, acute renal failure) are considered clinically relevant hemolysis changes.

Up to Day 14
Time to recurrence of P. vivax malaria
Lasso di tempo: Up to Month 6

Recurrence is defined as a positive blood smear for P. vivax parasites within the 6-month follow-up period, after clearance of blood-stage parasitemia.

Up to Month 6
Number of participants with treatment emergent adverse events (TEAEs) up to Month 6
Lasso di tempo: Up to Month 6

An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Up to Month 6
Number of participants with TEAEs meeting >= Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 criteria
Lasso di tempo: Up to Month 6

Severity was graded according to DAIDS grading criteria, where Grade 1-mild, Grade 2-moderate, Grade 3-severe, Grade 4-potentially life-threatening, Grade 5-Death.

Up to Month 6
Number of participants with drug related TEAEs
Lasso di tempo: Up to Month 6

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Up to Month 6
Number of participants with serious AEs (SAEs)
Lasso di tempo: Up to Month 6

A SAE is any untoward medical occurrence that results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization or result in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant.

Up to Month 6
Number of participants with AEs resulting in treatment discontinuation
Lasso di tempo: Up to Month 6

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Up to Month 6
Number of participants with AEs leading to study withdrawal
Lasso di tempo: Up to Month 6

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Up to Month 6
Number of participants with AEs considered to be hematologically related
Lasso di tempo: Up to Month 6

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Up to Month 6
Liver chemistry changes meeting Hy's criteria
Lasso di tempo: Up to Month 6

Hy's criteria cases were defined as any elevated alanine aminotransferase (ALT) >=3 times upper limit of normal (ULN) and total bilirubin >=2 times ULN or ALT >=3 times ULN and international normalized ratio (INR) >1.5.

Up to Month 6
Number of participants with TEAEs up to Week 4
Lasso di tempo: Up to Week 4

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Up to Week 4
Change from baseline at each study visit for clinical chemistry parameters (ALT, AST, ALP)
Lasso di tempo: At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180

Data for alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP) is measured in international units/liter (IU/L).

At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
Change from baseline at each study visit for clinical chemistry parameters (CPK)
Lasso di tempo: At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180

Data for creatine phosphokinase (CPK) is measured in units per liter (U/L).

At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
Change from baseline at each study visit for clinical chemistry parameters (total bilirubin, indirect bilirubin, blood urea nitrogen [BUN]/Urea, and serum creatinine)
Lasso di tempo: At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180

Clinical chemistry parameters are measured in milligrams per decilitre (mg/dL).

At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
Change from baseline at each study visit for clinical chemistry parameters (serum electrolytes)
Lasso di tempo: At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180

Data for serum electrolytes is measured in millimoles per liter (mmol/L).

At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
Change from baseline at each study visit for haematology parameters (platelet count)
Lasso di tempo: At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180

Platelets are measured in number of platelets per microliter (µL).

At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
Change from baseline at each study visit for haematology parameters (red blood cell [RBC] count)
Lasso di tempo: At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180

Data for RBC is measured in millions of cells per microliter (number of RBCs x10^6/µL).

At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
Change from baseline at each study visit for haematology parameters (mean corpuscular volume [MCV])
Lasso di tempo: At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180

Data for MVC is measured in femtoliters (fL).

At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
Change from baseline at each study visit for haematology parameters (mean corpuscular hemoglobin [MCH])
Lasso di tempo: At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180

Data for MCH is measured in picograms (pg) per cell.

At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
Change from baseline at each study visit for haematology parameters (white blood cell count [WBC] with differential)
Lasso di tempo: At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180

Data for neutrophils, lymphocytes, monocytes, eosinophils and basophils is presented as a count, which measures a percentage (%) of the WBC.

At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
Change from baseline at each study visit for haematology parameters (hemoglobin)
Lasso di tempo: At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180

Hemoglobin is measured in grams per deciliter (g/dL).

At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180
Change from baseline at each study visit for haematology parameters (hematocrit)
Lasso di tempo: At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180

Hematocrit is measured in volume percentage (%) of RBC in blood.

At Days 5, 8, 15, 29, 60, 90, 120, 150 and 180

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

13 novembre 2024

Completamento primario (Stimato)

14 maggio 2027

Completamento dello studio (Stimato)

14 maggio 2027

Date di iscrizione allo studio

Primo inviato

18 ottobre 2024

Primo inviato che soddisfa i criteri di controllo qualità

29 ottobre 2024

Primo Inserito (Effettivo)

30 ottobre 2024

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

1 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

28 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 208550

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf

Periodo di condivisione IPD

Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Criteri di accesso alla condivisione IPD

Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • LINFA
  • ICF
  • RSI

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .